Abstract
Abstract
Background
Overexpression of the EpCAM (epithelial cell adhesion molecule) in malignancies makes it an attractive target for passive immunotherapy in a wide range of carcinomas. In comparison with full-length antibodies, due to the small size, the scFvs (single-chain variable fragments) are more suitable for recombinant expression in E. coli (Escherichia coli). However, the proteins expressed in large amounts in E. coli tend to form inclusion bodies that need to be refolded which may result in poor recovery of bioactive proteins. Various engineered strains were shown to be able to alleviate the insolubility problem. Here, we studied the impact of four E. coli strains on the soluble level of anti-EpEX-scFv (anti-EpCAM extracellular domain-scFv) protein.
Results
Although results showed that the amount of soluble anti-EpEX-scFv obtained in BL21TM (DE3) (114.22 ± 3.47 mg/L) was significantly higher to those produced in the same condition in E. coli RosettaTM (DE3) (71.39 ± 0.31 mg/L), and OrigamiTM T7 (58.99 ± 0.44 mg/L) strains, it was not significantly different from that produced by E. coli SHuffleTM T7 (108.87 ± 2.71 mg/L). Furthermore, the highest volumetric productivity of protein reached 318.29 ± 26.38 mg/L in BL21TM (DE3).
Conclusions
Although BL21TM (DE3) can be a suitable strain for high-level production of anti-EpEX-scFv protein, due to higher solubility yield (about 55%), E. coli SHuffleTM T7 seems to be better candidate for soluble production of scfv compared to BL21TM (DE3) (solubility yield of about 30%).
Funder
the Protein Technology Research Center, Shahid Beheshti University of Medical Sciences
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Zamani M, Hashemi A, Zarei N, Jahandar H (2019) Construction of recombinant yeast expressing EpEX as a suitable candidate in cancer diagnosis and therapy. Koomesh 21:735–742
2. Mohtar MA, Syafruddin SE, Nasir SN, Yew LT (2020) Revisiting the Roles of Pro-Metastatic EpCAM in Cancer. Biomolecules 10:255
3. Sa MV, Hashemi A, Keramati M, Rasouli Kery Bozorg F (2019) Effects of cultivation conditions on the expression level of recombinant scFv antibody against EpEX in Escherichia coli. Trends Pept Protein Sci 4:1–6
4. Eyvazi S, Farajnia S, Dastmalchi S, Kanipour F, Zarredar H, Bandehpour M (2018) Antibody based EpCAM targeted therapy of cancer, review and update. Curr. Cancer Drug Targets 18:857–868
5. Mohammadgholizad F, Hashemi A (2019) Construction of recombinant Pichia pastoris expressing single-chain antibody fragment against extracellular domain of EpCAM. Koomesh 21:743–750
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献